Bli medlem
Bli medlem

Du är här


Vitrolife AB (publ): Kato Ladies Clinic chooses EmbryoScope+ for improved IVF treatments

Kato Ladies Clinic in Japan, one of the world's largest IVF clinics,
has decided to invest in the newly launched time-lapse system
EmbryoScope+. The order comprises eight EmbryoScope+ time-lapse
incubators providing the Kato Ladies Clinic with a time-lapse
capacity of approximately 6000 treatments per year, making it the
largest time-lapse capacity in a single clinic in the world.

The first units will be installed during the fourth quarter 2016 and
the remaining units are planned to be installed during the first
quarter 2017. Kato Ladies Clinic and Vitrolife have also agreed to
perform a joint research project on the application of time-lapse in
assisted reproduction, in particular with regards to natural and low
stimulation cycles. "We are pleased to introduce time-lapse as a
standard of care and we are confident that the investment in
EmbryoScope+ will improve our pregnancy rates and efficiency even
further", says Dr Kato, owner of Kato Ladies Clinic.

"It is extremely satisfying that the prestigious Kato Ladies Clinic
has decided to invest in EmbryoScope+ and we are delighted to be able
to offer the clinic and their customers access to the latest
time-lapse technology on the market", says Marcus Hedenskog,
Vitrolife's regional director in Japan & Pacific.

EmbryoScope+ is a time-lapse system with an integrated incubator.
EmbryoScope+ builds on the same foundation as EmbryoScope, the
world's most used time-lapse system for IVF since 2009, but with a
larger capacity for 15 patients with up to 16 embryos per patient in
a single instrument. EmbryoScope+ has a small footprint, which is an
advantage for labs where space is limited and provides an efficient
workflow and optimised usage of clinic resources. EmbryoScope+ was
presented at the ESHRE conference this summer and was available for
purchase from October this year.

Gothenburg, November 18, 2016
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication, through
the agency of the contact person set out above, at 8.30 am CET on
November 18, 2016.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


Vitrolife is an international medical device Group. Vitrolife
develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling
of stem cells for therapeutic purposes.

Vitrolife has approximately 330 employees and the company's products
are sold in about 110 markets. The company is headquartered in
Gothenburg, Sweden, and there are also offices in Australia, China,
Denmark, France, Germany, Hungary, Italy, Japan, United Kingdom and
USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80
99. E-mail: Website:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.